Authors
Loading...
Preclinical study demonstrates that macrophage PD-L1 drives immune evasion in chronic myeloid leukemia mice, highlighting the therapeutic value of combined ponatinib and anti-PD1 therapy.
Lu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: